BDRX (Biodexa Pharmaceuticals) Net Interest Margin (Bank Only) %


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $3.14
GF Value $2.58
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $3.14 is trading 21.7% above its estimated GF Value™ of $2.58. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $2.58 vs. price of $3.14 (21.7% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.14
Price
$2.58
GF Value